2LBA Late Breaking - Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC)

B.C. Cho; J. Lin; D.R. Camidge; V. Velcheti; B. Solomon; S. Lu; K.H. Lee; S.W. Kim; S. Kao; R. Diadziuskzko; M. Beg; M. Nagasaka; E. Felip; B. Besse; C. Springfeld; S. Popat; J. Wolf; D. Trone; S. Stopatschinskaja; A. Drilon

doi:10.1016/S0959-8049(22)00812-7

YUHSpace

BROWSE

0 265

Cited 5 times in

2LBA Late Breaking - Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC)

Authors: B.C. Cho ; J. Lin ; D.R. Camidge ; V. Velcheti ; B. Solomon ; S. Lu ; K.H. Lee ; S.W. Kim ; S. Kao ; R. Diadziuskzko ; M. Beg ; M. Nagasaka ; E. Felip ; B. Besse ; C. Springfeld ; S. Popat ; J. Wolf ; D. Trone ; S. Stopatschinskaja ; A. Drilon